While the potential benefits of lecanemab are clear, some health policy experts and fiscal watchdogs are urging caution regarding the widespread public funding of the drug. The primary concern lies in the high cost of the medication combined with the significant infrastructure required to administer it. Because the drug requires regular infusions and frequent MRI scans to monitor for serious side effects like brain swelling or bleeding, the total cost to the healthcare system extends far beyond the price of the drug itself.
Critics argue that provincial health budgets are already stretched thin, and allocating massive resources to a treatment that provides only a modest slowing of cognitive decline may not be the most efficient use of taxpayer money. There is a fear that funding this drug could divert essential resources away from other areas of dementia care, such as home support services, respite care for families, and long-term care facilities, which serve a much larger portion of the patient population. The debate centers on whether the marginal clinical gain justifies the massive financial commitment required.
Additionally, there are concerns regarding the long-term safety profile of the drug. Because it is a relatively new treatment, the full scope of its side effects over several years remains somewhat uncertain. Skeptics suggest that a more measured approach, perhaps involving pilot programs or restricted access, would be more prudent until more real-world data is available. Ensuring that the healthcare system does not over-commit to a high-cost, high-risk treatment before its long-term value is fully established is a critical priority for those focused on fiscal and clinical accountability.